New York-based pharmaceutical firm SIGA Technologies (NASDAQ:SIGA) is among the companies to benefit from the growing threat of monkeypox, recently pushing its shares to an almost decade-high after the company obtained approval in Europe to use its TPOXX antiviral drug for the treatment of monkeypox.
Smallpox jabs vs monkeypox
On May 19, the World Health...
were up 15% AH and trying to consolidate if we can hold the $0.49 area and stay out of oversold stoch on the daily beating $0.545 and breaking $0.668 level stock should revisit the $0.71-$0.78 area predicting rangebound price action
The stock has broken out and retested, therefore may undergo a reversal rally. Trade is supported by Supports Nearby.
Risk Reward Ratio - 2:1
SL is placed below the support zone & the lower trendline. The target is placed near resistance.
ATER has traded down to a support level and 0.62 Fib retracement. ATER has an upcoming pharmaceutical approval from the FDA for one of their drugs which remains in stage 2 trials.
$INNO.CN stock grew by +3.39% on Friday, stock opened at $0.590 and closed at $0.610, meanwhile price action is working above 20 EMA in daily chart that shows stock is bullish in nature and MACD is also showing strength in stock. RSI is close to par, indicating that current share price is fairly valued. The market cap of the company is 159.073M, and its average...
Pfizer's W-4 bottomed right in our "Buy Zone" and has bounced 10% since. I expect Pfizer to continue to climb up to the $58-60 level over the coming 2 weeks or so. After that, Pfizer will pull back for it's larger degree W-2, which should bring price back to about the $50 level. We will have more clarity on pullback targets once W-5 tops, most likely in our...
ARDS Aridis Pharmaceuticals has 2 Phase 3 Clinical Trials for 2022, one Phase 2a study, a fully human monoclonal antibody (mAb) cocktail against COVID and a funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19.
And the Market Cap is only...
NRx Pharmaceuticals, Inc. (NRXP) has two Phase III assets for which it has Fast Track and Breakthrough Therapy designation, respectively: intravenous ZYESAMI® for Critical COVID-19 and NRX-101 for bipolar depression with suicidality.
52 Week Range 2.38 - 48.80.
in 2020 the stock was $77.
My price target is 16.50
If this is not the time to buy this stock, then when?!
Mid-cap Pharma Company might get a booster dose?
The 31,177.59 Cr. worth mid-cap Pharma company, Laurus Labs Ltd. gave a massive 96% CAGR (3yrs.) in the past. The share price of the company made a high of Rs. 723.55 after which it saw a downturn is now giving signals of its trend reversal to Bullish. The share price of the company made an 'inverted Head and...
Palisade Bio, Inc. (PALI) plans to initiate a phase 3 study for accelerating the return of bowel function in the first half of 2022 and for the first patient to be enrolled in the second half of 2022.
On 2/2/2022 LADENBURG THALM/SH SH brokerage Initiated Coverage for PALI with a Buy rating and $5.00 Price Target.
Market Cap 12.841Mil
52 Week Range 0.76 -...
Wock Pharma at very strong support . i used 4 hour time frame to analysis the above stock . entry and exit are based on P &F charts 1% box reversal method . why i choose the point and figure is the method give you exact price to enter and exit . please use stop loss .
Took a little nibble on NVNO. Chat doesnt look to bad with price at the bottom of the range and making a nice W. The book also look pretty clean with a low share count finviz.com
DIVISLAB have taken support and forming pole and flag . Going to break channel and start up move. Targets are mentioned, must comment if have any suggestion. NSE:DIVISLAB
Buying Moderna here, may be printing a double bottom on weekly. They arent going to let this pandemic go away so banking on more vaccines and more fun for a few more years at least. It is still WAY up from a few years ago so setting tight stops. Not advise.
CWBR closed 2 months ago a $15.0 Million Public Offering of Common Stock and Warrants at $0.72, so this is a safe upside in my opinion if you want to enter now.
On the other hand, Cantor Fitzgerald brokerage has a $2.5 price target for it.
52 Week Range 0.34 - 2.27 Just bounced from its lowest support.
The stock has broken out and retested, therefore may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby.
Risk Reward Ratio - 2.5:1
SL is placed below support zone & the lower trendline. The target is placed near resistance.
